相似文献
1
RLF-MYCL fusion: A new tool for treatment of small cell lung cancer.
Thorac Cancer. 2022 Jan;13(1):147-148. doi: 10.1111/1759-7714.14253. Epub 2021 Dec 1.
2
Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer.
Cancer Discov. 2021 Dec 1;11(12):3214-3229. doi: 10.1158/2159-8290.CD-21-0441.
3
The molecular approach to diagnosis in lung cancer.
Br J Hosp Med (Lond). 2015 May;76(5):C74-6. doi: 10.12968/hmed.2015.76.5.C74.
4
PLEKHM2-ALK: A novel fusion in small-cell lung cancer and durable response to ALK inhibitors.
Lung Cancer. 2020 Jan;139:146-150. doi: 10.1016/j.lungcan.2019.11.002. Epub 2019 Nov 6.
5
MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
Oncotarget. 2016 Nov 22;7(47):77378-77388. doi: 10.18632/oncotarget.12671.
6
A rare case of an EML4-ALK-rearranged lung adenocarcinoma missed by in situ-hybridization but detected by RT-PCR.
J Clin Pathol. 2014 Sep;67(9):839-40. doi: 10.1136/jclinpath-2014-202394.
7
Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
J Thorac Oncol. 2018 Jul;13(7):987-995. doi: 10.1016/j.jtho.2018.04.016. Epub 2018 Apr 25.
8
Circular RNA F-circEA produced from EML4-ALK fusion gene as a novel liquid biopsy biomarker for non-small cell lung cancer.
Cell Res. 2018 Jun;28(6):693-695. doi: 10.1038/s41422-018-0033-7. Epub 2018 Apr 8.
9
First case of combined small-cell lung cancer with adenocarcinoma harboring EML4-ALK fusion and an exon 19 EGFR mutation in each histological component.
J Thorac Oncol. 2012 Dec;7(12):e39-e41. doi: 10.1097/JTO.0b013e3182762bcb.
10
Multiplex genomic test of mutation and fusion genes in small biopsy specimen of lung cancer.
J Exp Ther Oncol. 2016 Jul;11(3):189-194.
本文引用的文献
1
Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer.
Cancer Discov. 2021 Dec 1;11(12):3214-3229. doi: 10.1158/2159-8290.CD-21-0441.
2
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
3
Small-cell lung cancer.
Nat Rev Dis Primers. 2021 Jan 14;7(1):3. doi: 10.1038/s41572-020-00235-0.
4
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
J Clin Oncol. 2020 Jul 20;38(21):2369-2379. doi: 10.1200/JCO.20.00793. Epub 2020 May 29.
5
Cancer burden of major cancers in China: A need for sustainable actions.
Cancer Commun (Lond). 2020 May;40(5):205-210. doi: 10.1002/cac2.12025. Epub 2020 May 2.
6
New Approaches to SCLC Therapy: From the Laboratory to the Clinic.
J Thorac Oncol. 2020 Apr;15(4):520-540. doi: 10.1016/j.jtho.2020.01.016. Epub 2020 Feb 1.
7
Pathological transition as the arising mechanism for drug resistance in lung cancer.
Cancer Commun (Lond). 2019 Oct 1;39(1):53. doi: 10.1186/s40880-019-0402-8.
8
Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?
Cancer Commun (Lond). 2019 Apr 29;39(1):22. doi: 10.1186/s40880-019-0368-6.
9
Molecular analysis of cell-free DNA identifies distinct molecular features in patients with chemosensitive and chemorefractory small cell lung cancer.
Cancer Commun (Lond). 2019 Apr 18;39(1):20. doi: 10.1186/s40880-019-0363-y.
10
Intertumoral Heterogeneity in SCLC Is Influenced by the Cell Type of Origin.
Cancer Discov. 2018 Oct;8(10):1316-1331. doi: 10.1158/2159-8290.CD-17-0987. Epub 2018 Sep 18.
Zotero 插件